A comprehensive view of Genmab A/S. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Genmab investing US$32.6M to expand its US headquarters in Plainsboro, New Jersey, by 135,000 square feet, creating 300 jobs in an effort to increase commercialization of Epkinly, its recently approved lymphoma drug
Published: March 29, 2024 by FiercePharma
FDA grants priority review to AbbVie's SBLA for epcoritamab-bysp, a subcutaneously administered T-cell engaging bispecific antibody for the treatment of adult relapsed or refractory follicular lymphoma; AbbVie and Genmab are co-developing epcoritamab
Published: February 27, 2024 by AbbVie Inc.
FDA accepts Pfizer and Genmab's sBLA for full approval of cervical cancer treatment Tivdak tisotumab vedotin-tftv, granting priority review with a target date of May 9, 2024; the medicine previously received accelerated approval
Published: January 11, 2024 by PharmaBiz (India)
INTERNATIONAL PATENT: BIONTECH SE, GENMAB A/S FILES APPLICATION FOR "MONOCLONAL ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 PROTEIN AND THEIR USE IN MEDICINE"
Published: November 20, 2023 by U.S. Fed News
INTERNATIONAL PATENT: GENMAB A/S, BIONTECH SE FILES APPLICATION FOR "BINDING AGENTS CAPABLE OF BINDING TO CD27 IN COMBINATION THERAPY"
Published: November 20, 2023 by U.S. Fed News

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count